Article3 Biotech2025
Exploration of mechanism of anticancer potential of fisetin nanoformulations: nanotized fisetin/fisetin loaded polymannose nanoparticles in the treatment of triple negative breast carcinoma.
Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) remains one of the most aggressive and difficult-to-treat subtypes of breast cancer due to the lack of targeted therapies. This study investigates the anti-proliferative and anti-metastatic potential of fisetin (FIS) and its nanoformulations, nanotized fisetin (Nano-FIS) and FIS-loaded polymannose nanoparticles (FIS-PM NPs) in TNBC cells. Both Nano-FIS and FIS-PM NPs demonstrated significant, time- and dose-dependent cytotoxicity, with FIS-PM NPs showing the greatest inhibition of cell viability. Morphological assessments revealed pronounced apoptotic features, including cell shrinkage and rounding, particularly in nanoformulation-treated cells. In vitro wound healing assays confirmed that Nano-FIS and FIS-PM NPs markedly delayed cell migration compared to free FIS, indicating strong anti-metastatic properties. Western blot analysis further revealed that treatment with the nanoformulations downregulated pro-survival proteins NF-κB p65, Cyclin D1, and Bcl-2, while upregulating pro-apoptotic proteins Caspase-3 and Caspase-8, with FIS-PM NPs eliciting the most pronounced effects. RT-PCR analysis supported these findings by demonstrating significant downregulation of angiogenesis- and metastasis-related genes VEGF-A, VCAM1, MMP-9, and MMP-2 in nanoformulation-treated TNBC cells. Overall, the results suggest that FIS-based nanoformulations, particularly FIS-PM NPs, exhibit enhanced anti-cancer efficacy through the induction of apoptosis, inhibition of cell proliferation, migration, and angiogenesis, making them promising therapeutic candidates for TNBC treatment. Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-025-04427-x.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.